PET/CT Imaging Agent for COVID-19
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging agent, 18F-αvβ6-BP, to understand its effects on the lungs of people who have recovered from COVID-19. The goal is to determine how this imaging method can study lung changes after the virus. Participants will receive an injection of a special tracer before undergoing a PET/CT scan, which creates detailed pictures of the lungs. The trial seeks individuals who have had COVID-19, tested negative twice since, and had no lung disease before their infection. As an Early Phase 1 trial, this research focuses on understanding how this new imaging agent works in people, offering participants a chance to contribute to groundbreaking medical research.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this imaging agent is safe for use in PET/CT scans?
Research has shown that 18F-αvβ6-BP is a new substance being tested for use in PET/CT scans to examine the lungs after a COVID-19 infection. So far, a small number of patients have tried this substance. These early tests suggest it could safely identify changes in the lungs after the virus.
The current information on safety is limited, but no serious side effects have been reported in the patients tested. As this is an early phase trial, researchers focus on ensuring the treatment's safety. Treatments in early stages are generally closely monitored for safety, and any side effects are carefully recorded.
Overall, while more information is needed, early findings suggest that 18F-αvβ6-BP is well-tolerated by patients.12345Why are researchers excited about this trial?
Unlike standard COVID-19 treatments that focus on reducing symptoms or viral load, the 18F-αvβ6-BP treatment is unique because it uses a PET/CT imaging agent to help visualize the virus's impact on the lungs. Researchers are excited about this treatment because it targets the αvβ6 integrin, offering a new way to assess the disease's progression in real time. This imaging capability could lead to more precise monitoring and faster adjustments in patient care, potentially improving outcomes.
What evidence suggests that this imaging agent is effective for evaluating patients after COVID-19 infection?
Research has shown that 18F-αvβ6-BP, the investigational imaging agent used in this trial, is a promising tool for detecting lung damage in individuals who have had COVID-19. This agent is used with PET/CT scans, advanced types of X-rays. Studies have found that it can help visualize and track changes in the lungs after a COVID infection. It targets a specific protein in the lungs that often increases with damage. Early findings suggest it could be useful for monitoring lung healing over time.56789
Are You a Good Fit for This Trial?
This trial is for men and women over 18 who had COVID-19 but are now negative, with no prior lung diseases. They must have had a lung image taken during their infection and be able to stay still for up to an hour per scan. It's not for those with other respiratory infections, pregnant or breastfeeding women, patients too heavy for PET/CT scans (>350lbs), or anyone unlikely to attend follow-up sessions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive a 10 mCi (±20%) intravenous injection of 18F-αvβ6-BP, followed by PET/CT imaging to detect lung damage
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 18F-αvβ6-BP
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Davis
Lead Sponsor